Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A high molecular weight resin-polymer that decreases the intestinal absorption of bile acids and cholesterol.
Oral administration twice a day.
Since the last update we have not found data published in relation to breastfeeding.
The intestinal absorption of the drug is zero (AEMPS 2013, New Zealand Data Sheet 2010), so it can not transfer to breastmilk, nor to the infant’s plasma via breastmilk. Its high molecular weight makes it unlikely that it will transfer into breastmilk in significant amounts.
It is unlikely that it can alter the lipid composition of milk. Infants need to ingest large amounts of cholesterol, as it is essential for the proper development of the nervous system, cell membranes and is a precursor of several hormones and vitamins.
Prolonged use can cause plasma deficiency, due to lack of absorption of fat-soluble vitamins (A, D, E, K) so it may be advisable to supplement to avoid deficiency of these vitamins in breastmilk.
Various medical associations, experts and expert consensus consider the use of this medication safe during breastfeeding (Hale 2017 p195, Lawrence 2016 p393, Serrano 2015, Briggs 2015, Heetun 2007, Mahadevan 2006).
It is advisable to follow a lipid-lowering diet.
Halting the pharmacological treatment of hypercholesterolemia during the period of breastfeeding is not likely to significantly alter the long-term outcome of the disease.